Make room in your next appointment for the questions that matter to you. Use this guide to organize the conversation and keep a record of the answers.
Key takeaways
- Prepare one question that matters most to you.
- Bring the current pack and prescription.
- Record the answers and a contact for follow-up.
1. What this guide helps you do
Use this guide to prepare a conversation, not to choose treatment. Detailed contraindications, interactions, monitoring, missed-dose and pregnancy/breastfeeding instructions are outside its scope; use your full local leaflet and team.
2. Which medicine is covered
Selected pack: UK Provera 100 mg oral medroxyprogesterone acetate, PL 00057/1032, for GB readers. [A] [B] The label lists certain hormone-dependent cancers: endometrial, renal cell, and breast cancer in postmenopausal women. [A] Match your actual product; other forms are not interchangeable instructions.
3. Clarify the reason
Ask: “Why is this medicine being considered for my diagnosis?” Repeat the explanation in your own words and ask what you have missed.
4. Discuss the decision
Before deciding, ask: “What other options should I understand, and why do you think this one fits?” This guide compares no outcomes and offers no independent trial-funding or drug-supply verdict.
5. Keep daily life in view
Tell the team what is hardest in daily life and what you hope to get back to. Ask how the care plan will fit those priorities; no supplement or lifestyle therapy is assessed here.
6. Agree on review points
Agree on what you need to know after the appointment: the intended goal, next review and who will explain the results. Ask how the team will weigh benefit against problems you report.
7. Safety before the next appointment
For leaflet emergency symptoms—including sudden chest pain, breathlessness, speech difficulty or facial swelling with breathing difficulty—stop the tablets and seek emergency medical help immediately. [B] This is not the full warning list. For a first seizure, call 999 for an ambulance in the UK; elsewhere use local emergency services. [C] Existing epilepsy plans can differ; this general triage is separate from medicine-stop rules.
Meningioma is a tumour around the brain or spinal cord. Report new vision changes or worsening headaches to your doctor straightaway. The oncology label and safety letter require case-by-case reconsideration after diagnosis. [A] [P] The leaflet says the doctor will reconsider, yet includes meningioma under its immediate-stop header. [B] Clarify this with your specialist; emergency symptoms follow the instruction above.
8. Prepare the medicines review
Bring a single list of everything you use, including products bought online. Ask who should check it before anything is added or changed.
9. Discuss personal suitability
Ask which parts of your history the team needs to check, and what the decision depends on. This guide cannot assess personal suitability.
10. Confirm the written instructions
Leave with instructions you can understand and a named contact for uncertainty between visits. Have the written prescription matched to the pack; this page supplies no amount or timing.
11. Bring research claims carefully
If a research claim is driving your questions, bring the original link and ask what was actually tested. This guide does not evaluate animal or laboratory evidence.
12. Funding and source credibility
Research funding at a glance
24 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
Tier records financial interests; grade appraises credibility within its stated scope. Maker-issued outcome claims carry D here; product documents remain authoritative for their own safety instructions. Company-disclosure grades do not imply filed facts are false. Agency support does not establish industry-free trials. Accuracy incentives below are editorial assessments. The source base is mainly UK, with US originals; country is not a reliability guarantee.
The company-filed England publisher-control route is Datapharm Limited → Summer Bidco Limited → Summer Midco Limited → Summer Topco Limited → CGE Partners LLP. [H] [I] [J] [K]
| Source | Country and funding | Tier / grade | Accuracy incentive and gap |
|---|---|---|---|
| [A] 100 mg label | UK Pfizer Limited. Commercial product issuer; emc subscription carrier [E]. | Tier 4 / D (maker-issued outcome claims) | Accuracy: Regulation, safety duties and liability. Gap: Company instructions; no independent trial-funding proof. Other strengths supply context, not a prescription. |
| [B] Cancer pack leaflet | UK Pfizer Limited; Pfizer Italia S.r.l., Italy manufacturer. Commercial product issuer; emc subscriptions [E]. | Tier 4 / D (maker-issued outcome claims) | Accuracy: Patient safety, regulation and liability. Gap: Primary pack instructions; unresolved label/leaflet tensions need specialist advice. |
| [C] NHS seizure triage | UK NHS. Declared DHSC public/no-sponsorship policy [D]. | Tier 2 provisional / B provisional | Accuracy: Public accountability and declared clinical sign-off. Gap: UK999 scope; page contributors/evidence ties undisclosed. |
| [D] NHS policy | UK NHS/DHSC. Declared public support; no advertising or corporate sponsorship. | Tier 2 provisional / B provisional | Accuracy: Public accountability and stated review/sign-off. Gap: Institutional self-description; review overdue; individual execution/ties unverified. |
| [E] emc publisher | UK Datapharm Limited. Owns/manages emc; pharmaceutical subscriptions; companies prepare/publish approved documents. | Tier 3 / C (interested publisher) | Accuracy: Subscriber trust and publishing reputation. Gap: Commercial hosting is not independently funded efficacy; subscription terms are undisclosed. |
| [F] Pfizer UK notes | UK Pfizer Limited. Reported immediate controller Pfizer Shareholdings Intermediate SARL (Luxembourg); ultimate Pfizer Inc. (US) [X]. Registry fees/public carrier [L] (Tier 2/B provisional). | Tier 4 / D (company self-disclosure) | Accuracy: Reporting duties and investor scrutiny. Gap: Selected dated notes; not beneficial-owner, private-flow or trial/drug-supply verification. Custody does not validate assertions. |
| [G] Pfizer revenue report | US Pfizer Inc., Delaware. Commercial product, alliance and royalty revenue. | Tier 4 / D (company self-disclosure) | Accuracy: Securities duties, liability and investor scrutiny. Gap: Cover/operations only; no complete accounts, ownership or original-trial/drug-supply audit. |
| [H] Datapharm filing | England, UK. Interested company-filed assertion; registry fee/public carrier [L] (Tier 2/B provisional). | Tier 4 / D (company self-disclosure) | Accuracy: Filing duties and public/legal scrutiny. Gap: Not independently registry-validated; no complete beneficial/funding disclosure. |
| [I] Summer Bidco filing | England, UK. Interested company-filed assertion; registry fee/public carrier [L] (Tier 2/B provisional). | Tier 4 / D (company self-disclosure) | Accuracy: Filing duties and public/legal scrutiny. Gap: Custody is not validation; ultimate funding/beneficial interests and private flows incomplete. |
| [J] Summer Midco filing | England, UK. Interested company-filed assertion; registry fee/public carrier [L] (Tier 2/B provisional). | Tier 4 / D (company self-disclosure) | Accuracy: Filing duties and public/legal scrutiny. Gap: Fresh access failed; retained link; custody is not validation or complete funding disclosure. |
| [K] Summer Topco filing | England, UK. Interested company-filed assertion; registry fee/public carrier [L] (Tier 2/B provisional). | Tier 4 / D (company self-disclosure) | Accuracy: Filing duties and public/legal scrutiny. Gap: Fresh access failed; active retained link; withdrawn statement excluded; complete funding not disclosed. |
| [L] Registry funding plan | UK Companies House, DBT executive agency. Company fees and departmental capital support. | Tier 2 provisional / B provisional | Accuracy: Public/legal accountability. Gap: Selected agency/funding sections; does not validate filings or disclose private company flows. |
| [M] 200 mg label | UK Pfizer Limited. Commercial product issuer; emc subscription carrier [E]. | Tier 4 / D (maker-issued outcome claims) | Accuracy: Regulation, safety duties and liability. Gap: Company instructions; no independent trial-funding proof. Other strengths supply context, not a prescription. |
| [N] 400 mg label | UK Pfizer Limited. Commercial product issuer; emc subscription carrier [E]. | Tier 4 / D (maker-issued outcome claims) | Accuracy: Regulation, safety duties and liability. Gap: Company instructions; no independent trial-funding proof. Other strengths supply context, not a prescription. |
| [O] Shared cancer leaflet; [O2] same PDF | UK Pfizer Limited; Italian manufacturer. Commercial product issuer; emc subscriptions [E]. | Tier 4 / D (maker-issued outcome claims) | Accuracy: Patient safety, regulation and liability. Gap: Shared safeguards; selected branded pack governs. The second PDF URL is byte-identical, not corroboration. |
| [P] Pfizer safety letter | UK Pfizer issuer; signed Seema Patel, Specialty Care Medical Director, Pfizer UK; MHRA host. Commercial Pfizer; MHRA fee/public support [Q]. Carrier Tier 2/B provisional. | Tier 4 / D (maker-issued outcome claims) | Accuracy: Safety duties, regulator agreement and liability. Gap: Injection-study evidence; no oral risk estimate or trial-funding audit. EEA annex is not UK licensing. |
| [Q] MHRA funding report | UK MHRA/DHSC. Industry fees, customer charges and public support. | Tier 2 provisional / B provisional | Accuracy: Public accounting and parliamentary scrutiny. Gap: Selected funding pages only; no project/trial or full financial audit. |
| [R] NHS tablet overview | UK NHS. Declared DHSC public/no-sponsorship policy [D]. | Tier 2 provisional / B provisional | Accuracy: Public accountability and declared clinical sign-off. Gap: Review overdue; contributors/evidence ties undisclosed; general page is not the cancer pack. |
| [S] NHS taking tablets | UK NHS. Declared DHSC public/no-sponsorship policy [D]. | Tier 2 provisional / B provisional | Accuracy: Public accountability and declared clinical sign-off. Gap: Review overdue; general missed-dose rule conflicts with cancer pack; contributor/evidence ties undisclosed. |
| [T] NHS reproduction | UK NHS. Declared DHSC public/no-sponsorship policy [D]. | Tier 2 provisional / B provisional | Accuracy: Public accountability and declared clinical sign-off. Gap: Review overdue; high-dose cancer needs specialist advice; general breastfeeding wording cannot override pack; ties undisclosed. |
| [U] NCI endometrial review | US NCI; reviewers Olga T. Filippova (Lenox Hill Hospital) and Marina Stasenko (NYU Medical Center). Public appropriations [W]; supported editorial boards [V]. | Tier 2 provisional / B provisional | Accuracy: Named reviewers, consensus and correction process. Gap: Selected qualitative context; specific conflicts undisclosed; original trial funding/drug supply unaudited. |
| [V] NCI board policy | US NCI. Board support, external-member honoraria/travel. | Tier 2 provisional / B provisional | Accuracy: Public accountability and editorial procedures. Gap: Recusal policy does not disclose specific conflicts or establish industry-free trials. |
| [W] NCI public funding | US NCI. Congressional appropriations. | Tier 2 provisional / B provisional | Accuracy: Public budget and legislative accountability. Gap: Agency support, not a study grant, drug-supply or personal-conflict record. |
| [X] Pfizer control filing | UK filing; US Pfizer interests. Interested company assertion; registry fee/public carrier [L] (Tier 2/B provisional). | Tier 4 / D (company self-disclosure) | Accuracy: Filing duties and public/legal scrutiny. Gap: Retained record, no fresh live verification; custody is not validation or full beneficial/trial funding disclosure. |
13. Questions about using this guide
Is this a treatment recommendation?
No. It is a guide for planning a conversation, not for choosing or changing treatment.
What if I leave with unanswered questions?
List them in order of importance and ask who can answer them before the next visit.
How can I use it with a carer?
Choose which questions you want help asking, and agree who will record the answers.
Does a source tier decide whether an instruction matters?
No. Tier records financial interests; credibility grades have a stated scope. The source profiles explain that distinction.
What should I do with a new research claim?
Bring the original link and the exact question it raises; ask how it relates to your own care.
14. Source notes and review date
Evidence checked: 6 October 2026. Each profile links an original. Educational research; no clinician certification.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.